{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T02:08:33Z","timestamp":1770516513049,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejca.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T06:31:48Z","timestamp":1502346708000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers"],"prefix":"10.1016","volume":"84","author":[{"given":"Y.C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Milne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Q.","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Picken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nesci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.6004\/jnccn.2016.0018","article-title":"Genetic\/familial high-risk assessment: breast and ovarian","volume":"14","author":"Daly","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2017.07.004_bib2","series-title":"Recommendations for management of women at high risk of ovarian cancer","author":"Cancer Australia","year":"2011"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/jmedgenet-2013-101974","article-title":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations","volume":"51","author":"Brohet","year":"2014","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.ejca.2017.07.004_bib4","first-page":"3776","article-title":"Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations","volume":"8","author":"Satagopan","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ejca.2017.07.004_bib5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5645","key":"10.1016\/j.ejca.2017.07.004_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.ejca.2017.07.004_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2017.07.004_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.07.004_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.ejca.2017.07.004_bib11","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.004_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ygyno.2012.08.023","article-title":"New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research","volume":"127","author":"Sherman","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2017.07.004_bib13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1470-2045(08)70308-5","article-title":"The cell of origin of ovarian epithelial tumours","volume":"9","author":"Dubeau","year":"2008","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.004_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/jwh.2013.4407","article-title":"Challenging and complex decisions in the management of the BRCA mutation carrier","volume":"22","author":"Stan","year":"2013","journal-title":"J Womens Health (Larchmt)"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.004_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.gyobfe.2013.08.020","article-title":"[Indications for prophylactic hysterectomy]","volume":"41","author":"Garabedian","year":"2013","journal-title":"Gynecol Obstet Fertil"},{"issue":"18","key":"10.1016\/j.ejca.2017.07.004_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.004_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.07.004_bib18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/modpathol.2012.169","article-title":"Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers","volume":"26","author":"Reitsma","year":"2013","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.004_bib19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.004_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2016.1773","article-title":"Drawing the line in risk-reducing gynecologic surgery in women with a BRCA mutation","volume":"2","author":"Leath","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.004_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ygyno.2006.01.006","article-title":"Role of prophylactic hysterectomy in patients at high risk for hereditary cancers","volume":"102","author":"Villella","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.07.004_bib22","article-title":"Surgical approach to hysterectomy for benign gynaecological disease","author":"Aarts","year":"2015","journal-title":"Cochrane Libr"},{"key":"10.1016\/j.ejca.2017.07.004_bib23","unstructured":"Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab)."},{"issue":"1","key":"10.1016\/j.ejca.2017.07.004_bib24","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/bcr1377","article-title":"Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource","volume":"8","author":"Mann","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2017.07.004_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5694\/j.1326-5377.2000.tb124064.x","article-title":"kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer","volume":"172","author":"Osborne","year":"2000","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10689-004-6129-x","article-title":"Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort","volume":"4","author":"Phillips","year":"2005","journal-title":"Fam Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2017.07.004_bib27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage C","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"9880","key":"10.1016\/j.ejca.2017.07.004_bib28","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.004_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2005.10.026","article-title":"Comparison of uterine malignancies that develop during and following tamoxifen therapy","volume":"101","author":"Ferguson","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2013.02.023","article-title":"Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial","volume":"129","author":"Brinton","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"9233","key":"10.1016\/j.ejca.2017.07.004_bib32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2016.03.002","article-title":"Racial disparity in survival of patients with uterine serous carcinoma: changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011","volume":"143","author":"Mahdi","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.07.004_bib34","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/AOG.0b013e3181c33c72","article-title":"ACOG Committee Opinion No. 444: choosing the route of hysterectomy for benign disease","volume":"114","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.004_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10397-013-0781-9","article-title":"Abdominal versus laparoscopic hysterectomies for benign diseases: evaluation of morbidity and mortality among 465,798 cases","volume":"10","author":"Wiser","year":"2013","journal-title":"Gynecol Surg"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.004_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.004_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3816\/CBC.2007.n.057","article-title":"National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women","volume":"7","author":"Goss","year":"2007","journal-title":"Clin Breast Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2017.07.004_bib38","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"10.1016\/j.ejca.2017.07.004_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"10021","key":"10.1016\/j.ejca.2017.07.004_bib40","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T06:43:50Z","timestamp":1569998630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":40,"alternative-id":["S0959804917311127"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}